292 related articles for article (PubMed ID: 11701695)
1. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
4. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.
Urhan M; Dadparvar S; Mavi A; Houseni M; Chamroonrat W; Alavi A; Mandel SJ
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1012-7. PubMed ID: 17256140
[TBL] [Abstract][Full Text] [Related]
5. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
6. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
7. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
9. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
Küçük ON; Gültekin SS; Aras G; Ibiş E
Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
[TBL] [Abstract][Full Text] [Related]
11. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
[TBL] [Abstract][Full Text] [Related]
12. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.
Sherman SI; Tielens ET; Sostre S; Wharam MD; Ladenson PW
J Clin Endocrinol Metab; 1994 Mar; 78(3):629-34. PubMed ID: 8126134
[TBL] [Abstract][Full Text] [Related]
14. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
15. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?
Khorjekar GR; Van Nostrand D; Garcia C; O'Neil J; Moreau S; Atkins FB; Mete M; Orquiza MH; Burman K; Wartofsky L
Thyroid; 2014 Sep; 24(9):1394-9. PubMed ID: 24820222
[TBL] [Abstract][Full Text] [Related]
16. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
17. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
[TBL] [Abstract][Full Text] [Related]
18. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
19. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
